Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer

Authors:

Abstract
Prostate-specific membrane antigen (PSMA) is a cell surface membrane protein highly expressed on prostate cancer cells.1,2 Lutetium Lu 177 vipivotide tetraxetan (Lu-177) PSMA was approved by the US Food and Drug Administration March 23, 2022, for the treatment of PSMA-positive, metastatic castration-resistant prostate cancer (mCRPC) previously treated with an androgen receptor pathway inhibitor and taxane-based chemotherapy.3 Lu-177 PSMA, consisting of a beta particle emitter that is linked to a PSMA-binding ligand, selectively binds to PSMA and delivers high doses of radiation to prostate cancer cells, causing their death.4-7

This publication has 19 references indexed in Scilit: